Findacure is a UK charity that is building the rare disease community to drive research and develop treatments. We work to: 1) Empower patient groups to build their patient community, develop as a charity and drive research; 2) Promote collaboration between rare disease stakeholders to facilitate treatment development for all.
Watch our member showcase video here https://bit.ly/3rhRi2D
Main activities are: fundraising for early stage life science companies, helping companies become investment ready; advice on obtaining R&D grants; interim and financial management for early stage companies; and contributing to board decisions as non-executive director. Experience includes raising equity for eight life science companies and obtaining R&D grants for 16 others. Also 12 years managing small companies and a number of non-executive director posts.
The Company's strong balance sheet makes Proximagen one of the best capitalised biotechnology companies in the small and mid cap European biotech sector.. . Proximagen is developing a broad pipeline of drug candidate programmes and has plans for substantial future growth through a strategy of acquisition and consolidation in its preferred therapeutic area of the central nervous system.. . Proximagen's Corporate Objectives:. . * Expanding our pipeline within CNS through in-house discovery, acquisition, in-licencing and partnering, thus building quality and critical mass in research and development.. * Offer a rewarding corporate culture to motivate and retain our employees.. * Retention of strong downstream participation in all commercialised programs. . . Proximagen is committed to the best interests of patients, the medical profession, our employees and our communities, and to seeking significant returns for our shareholders, based on the continuous pursuit of scientific and operational excellence.
Bicycle has developed a proprietary bicyclic peptide technology that enables the discovery of a new class of drug candidates with antibody-like selectivity and specificity. The company is well financed by a group of top-tier VCs and is applying the technology to drug discovery projects in several therapeutic areas. The company also plans to also enter selected research collaborations to make the platform available to pharma partners.
Bidwells is the leading property consultancy in the Oxford-Cambridge Arc, advising on over half of all science and technology space in the region. We manage over £5.2bn in property assets for national and international investors, and serve as a gateway to highly attractive markets for science and technology corporations and investors. We help businesses to find or develop new office and laboratory space, project manage fit-outs and refurbishments, and we provide building and planning consultancy, relocation and acquisition advice, and lease consultancy.
Biocair is a global GDP logistics specialist with over 35 years of experience in the pharmaceutical, biotechnology and life sciences sectors.
The company has built up a unique, client-centric approach by employing scientists in front-line logistics positions and assembling a team of best-in-class industry experts in quality, cold chain and regulatory compliance. Biocair focuses on providing the most comprehensive time-sensitive and temperature-controlled logistics services available whilst delivering flexible, tailored, cost-effective solutions to all clients.
The Biocair network operates 24/7 in over 160 countries across Europe, Africa, Asia and the Americas.
Watch our member showcase video here https://bit.ly/3K5dxBO
Research and Development in DNA Manipulation
Biofidelity’s mission is to improve and extend cancer patients’ lives by enabling better targeting of therapies, early detection of treatment resistance, and routine monitoring of treatment response. Our unique technology is designed to allow rapid, broad adoption of our assays in testing labs around the world, enabling a step change in patient care.